According to a recent Technavio market report, the clinical immunoassay analyzer market in the US is expected to grow at a CAGR of 6.04% during the period 2016-2020.
Immunoassay analyzers perform biochemical tests to detect antibodies. In clinical laboratories, these analyzers are used to detect the presence and measure the concentration of substances in patient samples which are responsible for various medical conditions. Immunoassay applications include detection of infectious diseases, cardiac markers, endocrine hormone testing, proteins, and viral or bacterial determination. Modern analyzers can run an assay in multiple steps with various reagents being added and washed away so that multiple results can be obtained from one sample.
To calculate the market size, the Technavio report considered the revenue generated from the sales of immunoassay analyzers, which are used in clinical laboratories to detect infectious diseases such as human immunodeficiency virus (HIV) and hepatitis, cancer, therapeutic drug monitoring, and others.
While rising demand for next-generation immunodiagnostics is a major factor that drives the market's growth, the high cost of upgrading is considered to be a market challenge. According to the report, the paper-based electrochemical immunoassay device is a major market trend.
Abbott Diagnostics, Beckman Coulter, Siemens Healthcare Diagnostics, bioMérieux, and Roche Diagnostics are among the leading manufacturers of immunoassay systems, according to the report. Beckman Coulter offers the Access 2, a state-of-the-art platform with an intuitive operator interface, enhanced sample handling and innovative menu, promoting lab efficiency, standardization and cost effectiveness. The ADVIA Centaur from Siemens Medical Solutions Diagnostics is an automated random-access immunoassay system which features a comprehensive test menu for infectious diseases, thyroid, fertility and anemia, as well as assays for cancer markers, cardiac analysis, allergy testing and therapeutic drug monitoring.